Louis, MO, USA), and the remaining intrahepatic mononuclear Palbociclib in vitro cells (IHMC) were washed twice in PBS and resuspended in RPMI 1640 medium (Gibco Invitrogen Corp., Grand Island, NY, USA). For isolation of peripheral blood mononuclear cells (PBMC), venous blood was collected into microtainer tubes containing K2EDTA (BD). Erythrocytes were lysed with RBC lysis buffer, and the remaining PBMC were washed twice in PBS and resuspended in RPMI 1640 medium. Four-colour staining of IHMC or PBMC was performed using a combination of the following mAb: Fluorescein isothiocyanate-anti Vβ TCR screening

panel, PE-anti-CD45RB (16A), PerCP-anti-CD8α (Ly-2), APC-anti-CD44 (IM7) (BD Biosciences, San Jose, CA, USA). Briefly, 2–10 × 105

IHMC or PBMC were resuspended in cold assay buffer [PBS containing 1% bovine serum albumin (Sigma) and 0·01% sodium azide] and incubated with anti-FcR 24G2 (BD Biosciences) and 0·5 μg of the relevant mAb at 4°C for 30 min. Cells were washed twice and resuspended in cold assay buffer. Flow cytometry was performed on a FACSCalibur (BD Biosciences) and data analysis was performed using FlowJo software (Tree Star, Inc., Ashland, OR, USA). We have shown that repeated immunization with Pbγ-spz induces long-lasting Selleckchem Lorlatinib protective immunity that is associated with liver memory CD8+ T cells (8). In the first set of experiments, we wanted to confirm Tolmetin the induction of the two main sets of memory CD8+ T cells following immunizations with Pbγ-spz and following challenge with infectious

spz. Hepatic CD8+ T cells were isolated from unimmunized, or mice immunized with three doses of Pbγ-spz, and analysed for the expression of the activation-related cell surface markers, CD44 and CD45RB. Consistent with our previous observations, hepatic CD8+ T cells from unimmunized mice consisted of two distinct populations: naïve CD8+ T cells (TN) (CD44loCD45RBhi) (81·6 ± 1·3% of CD8+ T cells; 2·4 ± 0·3 × 105 total cells) and CD8+ TCM cells (CD44hiCD45RBhi) (11·5 ± 1·9% of CD8+ T cells; 3·4 ± 0·7 × 104 total cells) (Figure 1a). Following immunization with Pbγ-spz, CD8+ TEM cells (CD44hiCD45RBlo) appeared in the liver (33·9 ± 1·7% of CD8+ T cells; 4·8 ± 1·0 × 105 total cells) and these cells further increased after challenge with infectious spz (44·3 ± 2·9% of CD8+ T cells; 6·0 ± 1·3 × 105 total cells). The frequency of CD8+ TCM cells remained unchanged following Pbγ-spz immunization (15·2 ± 0·8% of CD8+ T cells) and challenge (13·4 ± 0·8% of CD8+ T cells). In contrast, the frequency of CD8+ TN cells was greatly reduced after immunization (44·3 ± 2·1% of CD8+ T cells) and challenge (36·5 ± 3·2% of CD8+ T cells). Eight weeks post-challenge, a significant population of CD8+ TEM cells was still detectable in the liver (32·3 ± 3·5% of CD8+ T cells; 2·2 ± 0·5 × 105 total cells).